Curagen (CRGN) Inactive 10-K2004 FY Annual report

Filed: 14 Mar 05, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: abandoned, ADC, afflicted, agent, amplification, antimicrobial, Applera, appraisal, appraised, ASH, Asia, assert, assuming, attached, bankruptcy, Biotage, bloodstream, bone, budget, calculation, category, cautionary, center, collusion, concentrated, concentration, conference, conjugate, consecutive, consent, COSO, court, cycle, deacetylase, deadly, death, delivery, detect, detected, detection, deteriorate, dexamethasone, Diarylquinoline, differentiated, differentiation, directly, dismissed, displaying, disposition, diversification, dose, EITF, endeavor, error, Europe, excluding, fast, fever, firm, framework, frequent, GE, geographically, global, Gloucester, guidance, HDAC, heading, hematologic, hematological, Hematology, hematopoietic, highlighted, histone, HSCT, hypotension, IgA, improper, indeterminate, infusional, inhibit, inhibitor, input, inScience, inside, intravenously, IPO, irradiation, issuable, Johnson, journalScience, label, linker, longest, male, mammalian, marrow, mechanistic, melanoma, melphalan, Merck, mitigate, Modernization, modified, mucosatoxic, Multinational, myeloablative, myeloma, nausea, NCI, nephropathy, NHGRI, NIH, nonmonetary, North, observed, ofMycobacterium, OM, opposed, override, Oversight, owed, payload, persuasive, pertain, petition, placebo, populace, poster, potency, potent, preliminarily, preserve, printed, proforma, pronouncement, properly, ready, reagent, regimen, rendered, reprioritized, rolling, salary, satisfactory, Seattle, sector, settle, settled, Shareholder, skin, solid, sparing, stable, statute, subscription, substance, Symposium, synergistic, Synthase, synthetic, tachycardia, Task, TBI, temporarily, tolerability, tolerated, TopoTarget, track, traditional, Treadway, tumor, unacceptable, unexpended, unvested, upfront, vacancy, volume, vomiting, waiting, xix, xx, xxi, xxii, xxiii, xxiv, xxix, xxv, xxvi, xxvii, xxviii, xxx, xxxi, xxxii, xxxiii, xxxiv

Removed: agreed, area, automated, bankrupt, capitalization, central, CII, covenant, cresswell, cure, Department, Device, estate, exercise, federally, fulfill, immune, lessor, medicine, Microfabricated, naturally, neurological, obesity, occupancy, organizational, powerful, Precise, presence, Programmable, prominent, psychiatric, real, relate, retroactively, ronald, secreted, superior, toxicology, Unaudited, unregistered, untrue, voting

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CRGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 12.1

CURAGEN CORPORATION AND SUBSIDIARY

RATIO OF EARNINGS TO FIXED CHARGES

(in thousands, except ratio data)


	Year Ended December 31,
	2004		2003		2002		2001		2000
Loss:
Loss before income tax benefit and minority interest in subsidiary loss	($97,231	)	($80,634	)	($95,793	)	($47,968	)	($28,706	)
Add: fixed charges	14,013		10,612		10,909		11,153		10,558

Total loss	($83,218	)	($70,022	)	($84,884	)	($36,815	)	($18,148	)

Fixed charges:
Interest expense on indebtedness (including amortization of financing costs)	$13,172		$ 9,830		$10,176		$10,553		$10,066
Estimated interest portion of rental expense	841		782		733		600		492

Total fixed charges	$14,013		$10,612		$10,909		$11,153		$10,558

Ratio of Earnings to Fixed Charges	(5.94	)	(6.60	)	(7.78	)	(3.30	)	(1.72	)

Deficiency of Earnings Available to Cover Fixed Charges	($97,231	)	($80,634	)	($95,793	)	($47,968	)	($28,706	)